CLOV: Revenue and profitability strengthened as FY26 guidance rose across all listed metrics
Clover Health Investments reported 3Q26 revenue growth of 53% YoY, with GAAP net income of $6M and Adjusted EBITDA of $16M. The company raised its FY26 guidance across all metrics, citing strong MA membership growth and a leading PPO quality rating, according to its slides release.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise suggest a short‑term upside opportunity for traders.
Market read
First report of earnings and guidance for CLOV; material for short‑term trading decisions.
What to watch
Potential regulatory changes in Medicare Advantage could affect future earnings.
Background
Clover Health released its Q3 FY26 slide deck with financial results and guidance.
Ticker impact
Q3 FY26 revenue up 53% YoY with GAAP net income $6M and adjusted EBITDA $16M; FY26 guidance raised across all metrics.
upward pressure as market prices in higher revenue growth and improved profitability.
The disclosed earnings beat expectations and guidance lift are fresh primary information for a small‑cap stock.
Market effects
Positive signal for the Medicare Advantage and health‑tech sector.
May lift other US health‑tech stocks in the near term.
Limited to US equity markets.
Counterpoint
Growth may be unsustainable; profitability remains modest and could face margin pressure.
Key entities
- companyClover Health Investments, Corp.
US‑listed health‑tech firm (ticker CLOV).
